Baidu
map

Rom J Ophthalmol:黄斑serporinous 脉络膜炎病例报告

2018-12-24 MedSci MedSci原创

罗马尼亚布加勒斯特儿童急救医院的Cozubas R和急救医院眼科的Ungureanu E等人,在Rom J Ophthalmol杂志上发表了一篇重要的病例报告,他们报告了一例黄斑serporinous 脉络膜炎病例,并对其诊断和治疗进行了讨论。

罗马尼亚布加勒斯特儿童急救医院的Cozubas R和急救医院眼科的Ungureanu E等人,在Rom J Ophthalmol杂志上发表了一篇重要的病例报告,他们报告了一例黄斑serporinous 脉络膜炎病例,并对其诊断和治疗进行了讨论。

Serpiginous脉络膜炎是不对称的、位于内脉络膜上的炎症,其与视网膜色素上皮和脉络膜毛细血管有关。有研究指出,这种疾病主要是特发性的,但有些作者认为,它是一种自身免疫的疾病。

很多时候,眼底自发荧光是指导进行诊断、治疗、随访以及对进展性视力预后进行诊断的重要方法。事实证明,局部治疗有时是一种有效的辅助治疗手段。

原文出处:

Cozubas, R., et al., Macular serpiginous choroiditis - case report. Rom J Ophthalmol, 2018. 62(3): p. 217-221.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1809801, encodeId=475e180980182, content=<a href='/topic/show?id=91658449502' target=_blank style='color:#2F92EE;'>#脉络膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84495, encryptionId=91658449502, topicName=脉络膜炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Jul 01 15:05:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687026, encodeId=206a168e02634, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Oct 10 00:05:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377015, encodeId=f55913e701513, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525151, encodeId=78b01525151d8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541420, encodeId=f65d154142050, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1809801, encodeId=475e180980182, content=<a href='/topic/show?id=91658449502' target=_blank style='color:#2F92EE;'>#脉络膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84495, encryptionId=91658449502, topicName=脉络膜炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Jul 01 15:05:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687026, encodeId=206a168e02634, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Oct 10 00:05:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377015, encodeId=f55913e701513, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525151, encodeId=78b01525151d8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541420, encodeId=f65d154142050, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1809801, encodeId=475e180980182, content=<a href='/topic/show?id=91658449502' target=_blank style='color:#2F92EE;'>#脉络膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84495, encryptionId=91658449502, topicName=脉络膜炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Jul 01 15:05:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687026, encodeId=206a168e02634, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Oct 10 00:05:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377015, encodeId=f55913e701513, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525151, encodeId=78b01525151d8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541420, encodeId=f65d154142050, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1809801, encodeId=475e180980182, content=<a href='/topic/show?id=91658449502' target=_blank style='color:#2F92EE;'>#脉络膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84495, encryptionId=91658449502, topicName=脉络膜炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Jul 01 15:05:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687026, encodeId=206a168e02634, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Oct 10 00:05:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377015, encodeId=f55913e701513, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525151, encodeId=78b01525151d8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541420, encodeId=f65d154142050, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-26 muzishouyi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1809801, encodeId=475e180980182, content=<a href='/topic/show?id=91658449502' target=_blank style='color:#2F92EE;'>#脉络膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84495, encryptionId=91658449502, topicName=脉络膜炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Jul 01 15:05:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687026, encodeId=206a168e02634, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Oct 10 00:05:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377015, encodeId=f55913e701513, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525151, encodeId=78b01525151d8, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541420, encodeId=f65d154142050, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:05:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]

相关资讯

Eye (Lond):为什么是黄斑?

英国伦敦大学学院眼科学院Bird AC近日在Eye (Lond)发表了一篇综述性文章,系统性的介绍了目前关于视网膜中不同区域的视网膜结构和功能的关系,并对视网膜营养不良症和黄斑等疾病进行了讨论。

J AAPOS:单侧贝伐珠单抗治疗对于早产儿视网膜病变的黄斑形态影响!

西澳大利亚西兰大学眼科研究所眼科和视觉科学中心的Clark A近日在J AAPOS杂志上发表了他们近期的一项工作,他们进行了回顾性病例研究,评估了单侧玻璃体内贝伐珠单抗(IVB)治疗在单侧1型早产儿视网膜病变(ROP)中对黄斑厚度和中央凹发育的影响。

Sci Rep:老年中国人进行常规白内障手术前使用光学相干断层扫描评估黄斑状态

南京医科大学附属无锡第二医院眼科的Huang X近日在Sci Rep发表了一项工作,他们对光谱域光学相干断层扫描(SD-OCT)在进行常规白内障手术患者术前隐匿性黄斑病变的识别能力进行了研究。

Ophthalmologica.:增生性糖尿病视网膜病变玻璃体切除术后黄斑在光学相干断层扫描上的结构变化

近日,来自韩国Sungkyunkwan大学、三星昌原医院眼科系的Shin JP医生及其团队在Ophthalmologica.杂志上发表了他们的最近研究:增生性糖尿病视网膜病变玻璃体切除术后黄斑在光学相干断层扫描上的结构变化。

Neurology:芬戈莫德治疗多发性硬化可增黄斑体积

  研究表明:MS患者接受芬戈莫德治疗与中等程度、相对快速的黄斑容积增加相关。   芬戈莫德是一种鞘氨醇-1-磷酸受体调节剂,是首个口服治疗多发性硬化的药物,在2010年获FDA批准用于多发性硬化的治疗,商品名Gilenya。为了研究芬戈莫德能否在总体上带来视网膜组织体积的增加,美国加州大学旧金山分校神经科多发性硬化研究中心的Rachel Nolan学士等人员进行了一项研究,研究结果发

FDA更新再生元Eylea处方信息

再生元(Regeneron)公司宣布,FDA已批准更新Eylea的美国处方信息,以回应美国视网膜专家关于标签语言曲解的社会关注问题。Eylea (aflibercept)用于治疗湿性年龄相关性黄斑变性、糖尿病性黄斑水肿和DME患者糖尿病视网膜病变。根据再生元公司的新闻稿,药物标签提到,初始每月给药期间之后,虽然大多数患者需要每8周接受一次治疗需要剂量,但是也有部分患者仍需要每月给药。发言人说道,“

Baidu
map
Baidu
map
Baidu
map